1 Min Read
Jan 3 (Reuters) - Marinus Pharmaceuticals Inc :
* Marinus Pharmaceuticals receives FDA orphan drug designation for Ganaxolone to treat Fragile X Syndrome Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.